Pages that link to "Q26852027"

The following pages link to Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists (Q26852027):

Displaying 40 items.

• The endogenous nociceptin/orphanin FQ-NOP receptor system as a potential therapeutic target for intestinal disorders (Q27011915) (← links)
• Distinct functions of opioid-related peptides and gastrin-releasing peptide in regulating itch and pain in the spinal cord of primates. (Q30655924) (← links)
• A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism (Q33729139) (← links)
• Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats. (Q34656938) (← links)
• Injury-Dependent and Disability-Specific Lumbar Spinal Gene Regulation following Sciatic Nerve Injury in the Rat (Q35612565) (← links)
• Neuraxial opioid-induced itch and its pharmacological antagonism (Q35659494) (← links)
• Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2. (Q35738904) (← links)
• Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates. (Q35846195) (← links)
• Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys (Q35865460) (← links)
• Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). (Q36043728) (← links)
• Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys (Q36733530) (← links)
• Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems (Q36744366) (← links)
• Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma (Q37084897) (← links)
• Central N/OFQ-NOP Receptor System in Pain Modulation (Q37094760) (← links)
• Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility (Q37211503) (← links)
• A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates (Q37264264) (← links)
• Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice (Q37340687) (← links)
• Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist (Q37591805) (← links)
• Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors (Q38417418) (← links)
• Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic (Q38721640) (← links)
• N/OFQ system in brain areas of nerve-injured mice: its role in different aspects of neuropathic pain. (Q39078235) (← links)
• Targeting multiple opioid receptors - improved analgesics with reduced side effects? (Q39221109) (← links)
• In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. (Q41380155) (← links)
• Minocycline enhances the effectiveness of nociceptin/orphanin FQ during neuropathic pain (Q42905505) (← links)
• Usefulness of knockout mice to clarify the role of the opioid system in chronic pain. (Q43075530) (← links)
• Altered expression of glial markers, chemokines, and opioid receptors in the spinal cord of type 2 diabetic monkeys (Q44340800) (← links)
• Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain (Q44342818) (← links)
• Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain. (Q44350191) (← links)
• In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. (Q45998228) (← links)
• Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial (Q47717136) (← links)
• Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad? (Q49602927) (← links)
• Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594; a novel fluorescent probe for the NOP receptor (Q57052932) (← links)
• Understanding the Agent, Part I: Opioid Biology and Basic Pharmacology (Q57462903) (← links)
• Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic (Q58545262) (← links)
• Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model (Q59806238) (← links)
• A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates (Q60650856) (← links)
• Analysis of the distribution of spinal NOP receptors in a chronic pain model using NOP-eGFP knock-in mice (Q88185439) (← links)
• Cellular Mechanisms for Antinociception Produced by Oxytocin and Orexins in the Rat Spinal Lamina II-Comparison with Those of Other Endogenous Pain Modulators (Q90133279) (← links)
• Opioid Receptors in Immune and Glial Cells-Implications for Pain Control (Q90479657) (← links)
• Modulation of the Negative Affective Dimension of Pain: Focus on Selected Neuropeptidergic System Contributions (Q92702908) (← links)